Inclusion Criteria
Articles were included if they met the following criteria: (1) prospective phase I-III randomized/nonrandomized or single-arm intervention studies conducted in patients diagnosed with GC or GEJC via pathology or cytology regardless of HER2 status; (2) studies including at least one arm treated with HER2-targeted ADC as a single agent; and (3) studies reporting at least one of the following outcomes: progression-free survival (PFS); overall survival (OS); objective response rate (ORR); disease control rate (DCR) and incidence of adverse events (AEs).